{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:32:29Z","timestamp":1785522749906,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03600-9","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:29:22Z","timestamp":1779258562000},"page":"3521-3534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Risk of Myelodysplastic Syndrome\/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Maurice J. D. L.","family":"van der Vorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanza","family":"Maximiano Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirza Areli","family":"Calder\u00f3n Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela A.","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Ma\u00f1\u00e9 Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judi","family":"Kuplast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Perhanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Golembesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"10","key":"3600_CR1","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833\u201348.","journal-title":"Ann Oncol"},{"issue":"33","key":"3600_CR2","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1200\/JCO.22.01934","volume":"40","author":"WP Tew","year":"2022","unstructured":"Tew WP, Lacchetti C, Kohn EC, PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022;40(33):3878\u201381.","journal-title":"J Clin Oncol"},{"key":"3600_CR3","unstructured":"European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer [press release]. October 29, 2020."},{"key":"3600_CR4","unstructured":"TESARO announces European Commission approval of ZEJULA\u00ae for women with recurrent ovarian cancer [press release]. November 20, 2017."},{"issue":"25","key":"3600_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"22","key":"3600_CR6","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"2","key":"3600_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ygyno.2021.05.034","volume":"162","author":"AC Casper","year":"2021","unstructured":"Casper AC, Parsons MW, Chipman J, Burt LM Jr, Suneja G, Maurer KA, et al. Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up. Gynecol Oncol. 2021;162(2):454\u201360.","journal-title":"Gynecol Oncol"},{"issue":"15","key":"3600_CR8","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","volume":"121","author":"LM Morton","year":"2013","unstructured":"Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975\u20132008. Blood. 2013;121(15):2996\u20133004.","journal-title":"Blood"},{"issue":"9","key":"3600_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME McNerney","year":"2017","unstructured":"McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17(9):513\u201327.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3600_CR10","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20(1):e15\u201328.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3600_CR11","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","volume":"8","author":"P-M Morice","year":"2021","unstructured":"Morice P-M, Leary A, Dolladille C, Chretien B, Poulain L, Gonzalez-Martin A, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8(2):e122\u201334.","journal-title":"Lancet Haematol"},{"key":"3600_CR12","doi-asserted-by":"publisher","first-page":"912256","DOI":"10.3389\/fphar.2022.912256","volume":"13","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Ma P, Fu P, Wang J, Wang K, Chen L, et al. Myelodysplastic syndrome\/acute myeloid leukemia following the use of poly-ADP ribose polymerase (PARP) inhibitors: a real-world analysis of postmarketing surveillance data. Front Pharmacol. 2022;13:912256.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3600_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ygyno.2018.09.003","volume":"151","author":"R Shenolikar","year":"2018","unstructured":"Shenolikar R, Durden E, Meyer N, Lenhart G, Moore K. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. Gynecol Oncol. 2018;151(2):190\u20135.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"3600_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJM199902043400504","volume":"340","author":"LB Travis","year":"1999","unstructured":"Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340(5):351\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"3600_CR15","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.annonc.2021.04.023","volume":"32","author":"PM Morice","year":"2021","unstructured":"Morice PM, Ray-Coquard I, Moore KN, Dieras V, Alexandre J. PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials. Ann Oncol. 2021;32(8):1048\u201350.","journal-title":"Ann Oncol"},{"key":"3600_CR16","unstructured":"Zejula: EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zejula-epar-product-information_en.pdf. Accessed July 21, 2025."},{"key":"3600_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2025.03.018","volume":"195","author":"UA Matulonis","year":"2025","unstructured":"Matulonis UA, Herrstedt J, Oza A, Mahner S, Redondo A, Berton D, et al. ENGOT-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: survival and long-term safety. Gynecol Oncol. 2025;195:192\u20139.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"3600_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2024;35(11):981\u201392.","journal-title":"Ann Oncol"},{"key":"3600_CR19","doi-asserted-by":"publisher","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","volume":"189","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, et al. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023;189:112908.","journal-title":"Eur J Cancer"},{"issue":"6","key":"3600_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","volume":"33","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Gonz\u00e1lez-Mart\u00edn A, Buckley L, Matulonis UA, Rimel BJ, Wu X, et al. Safety and management of niraparib monotherapy in ovarian cancer clinical trials. Int J Gynecol Cancer. 2023;33(6):971\u201381.","journal-title":"Int J Gynecol Cancer"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03600-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:18:43Z","timestamp":1785518323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03600-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3600"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03600-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Maurice J.D.L. van der Vorst has nothing to disclose. Constanza Maximiano Alonso reports payments for presentations and educational events from AstraZeneca, GSK, and MSD; travel support from AstraZeneca, GSK, and MSD; and participation on a data safety monitoring board or advisory board for AstraZeneca, GSK, and MSD. Judith R. Kroep reports grants from AstraZeneca, Novartis, and Philips; honoraria for participation in advisory boards from AstraZeneca, Daiichi Sankyo, Eisai, GSK, MSD, and Novartis; and travel support from Daiichi Sankyo. Juan Manuel Ma\u00f1\u00e9 Mart\u00ednez reports payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from AstraZeneca, GSK, and PharmaMar; and travel support from AstraZeneca, GSK, and PharmaMar. Giulia Tasca reports writing support from GSK; speaker fees from AstraZeneca and GSK; travel support from AstraZeneca, MSD, and PharmaMar; and participation on a data safety monitoring board or advisory board for Eisai, GSK, and MSD. Stefan Kommoss reports institutional grants from GSK; consulting fees from AstraZeneca, Eisai, GSK, MSD, and Novartis; participation on a data safety monitoring board or advisory board for AstraZeneca, Eisai, and GSK; and leadership or fiduciary role in AGO Study Group. Tirza Areli Calder\u00f3n Boyle, Izabela A. Malinowska, Guilan Ye, Judi Kuplast, Celeste Evans, and Amanda K. Golembesky are employed by GSK and hold financial equities in GSK. Jessica Perhanidis is employed by GSK and holds stock in Boston Scientific, GSK, and United Health Group. Jeanne M. Schilder is employed by GSK, holds financial equities in GSK, and also reports unpaid membership on the Board of Directors for the Little Red Door Cancer Agency.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles founded in the Declaration of Helsinki. Before study conduct, all study documentation was reviewed and approved by an institutional review board and independent ethics committee to safeguard the rights, safety, and well-being of patients. All patients completed a written informed consent form before enrollment, according to the regulatory and legal requirements of the participating country.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}